Tag: 上海松江区按摩

Take a Trip to Mars without Leaving Pasadena

first_imgScience and Technology Take a Trip to Mars without Leaving Pasadena From STAFF REPORTS Published on Wednesday, May 18, 2016 | 9:18 pm 6 recommended0 commentsShareShareTweetSharePin it Community News First Heatwave Expected Next Week Herbeauty10 Vietnamese Stunners That Will Take Your Breath AwayHerbeautyHerbeautyHerbeauty10 Ways To Get Into Shape You’ve Never Tried BeforeHerbeautyHerbeautyHerbeautyWeird Types Of Massage Not Everyone Dares To TryHerbeautyHerbeautyHerbeauty5 Things To Avoid If You Want To Have Whiter TeethHerbeautyHerbeautyHerbeautyWhat Is It That Actually Makes French Women So Admirable?HerbeautyHerbeautyHerbeauty10 Of The Most Notorious Female Spies In HistoryHerbeautyHerbeauty Name (required)  Mail (required) (not be published)  Website  Your email address will not be published. Required fields are marked * Subscribe Make a comment Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. Business Newscenter_img faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Virtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyCitizen Service CenterPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy Community News Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday Erisa Hines, a driver for the Mars Curiosity rover, based at JPL, also talks to participants in “Destination: Mars.” Credit: NASA/JPL-Caltech/MicrosoftA group of researchers at NASA’s Jet Propulsion Laboratory in Pasadena have been working on a new technology that will eventually allow scientists to work on Mars, in virtual reality – or, to be exact, “mixed reality.”Based on their research, NASA and Microsoft have teamed up to offer the public a guided tour of an area on Mars using mixed-reality headsets called OnSight. These will be unveiled in “Destination: Mars,” an interactive exhibit which opens at the Kennedy Space Center Visitor Complex in Florida this summer.A pilot group of scientists at JPL now uses OnSight in their work supporting the Curiosity Mars rover’s operations.“We’re excited to give the public a chance to see Mars using cutting-edge technologies that help scientists plan Curiosity’s activities on Mars today,” said Jeff Norris, project manager for OnSight and “Destination: Mars” at JPL. “While freely exploring the terrain, participants learn about processes that have shaped this alien world.”Using the mixed-reality devices, guests at “Destination: Mars” will virtually visit several sites on Mars, reconstructed from real imagery taken by NASA’s Curiosity Mars Rover which has been exploring the planet since 2012. Apollo 11 astronaut Buzz Aldrin will serve as a holographic tour guide on the journey.JPL’s Erisa Hines, who remotely drives Curiosity Mars rover, will also appear holographically, leading participants to places on Mars where scientists have made exciting discoveries and explaining what have been learned so far about the planet.“This experience lets the public explore Mars in an entirely new way. To walk through the exact landscape that Curiosity is roving across puts its achievements and discoveries into beautiful context,” said Doug Ellison, visualization producer at JPL.Abigail Fraeman, a Curiosity science team member at JPL, uses OnSight to make recommendations about where the rover should drive and which features to study in more detail. Recently OnSight helped her and a colleague identify the transition point between two Martian rock formations, which they would like to study in further detail.“OnSight makes the whole process of analyzing the data feel a lot more natural to me,” Fraeman said. “It really gives me the sense that I’m in the field when I put it on. Thinking about Martian geology is a lot more intuitive when I can stand in the scene and walk around the way I would if I were in the field.”“Destination: Mars,” utilizing the same technologies and datasets as OnSight , will offer participants a glimpse of Mars as seen by mission scientists at JPL.“The way a scientist would use this is that shortly after rover images come down from Mars, we will build a virtual version of Mars immediately and then stream it to their devices,” Alex Menzies, with JPL’s augmented-reality program, tells KABC. “They’ll be able to walk around on Mars, and identify potential new science targets, decide where they want to take pictures and plan out future drives of where they want to go.” Top of the News EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS More Cool Stuff Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadenalast_img read more

Read More

ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology

first_img Facebook TAGS  Previous articleRuling brings kosher slaughterhouse new business, old fearsNext articleCapco and Envizage Announce Strategic Partnership Digital AIM Web Support Facebook ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology By Digital AIM Web Support – January 28, 2021 LOS ANGELES and SAN DIEGO, Jan. 28, 2021 /PRNewswire/ — ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement. Under the terms of the agreement, ImaginAb will work with NEUVOGEN to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents into their therapeutic vaccine clinical trials, and provide technical and clinical support to NEUVOGEN’s development teams. ImaginAb will receive license fees and other contingent payments. No other terms were disclosed. ImaginAb’s PET imaging technology enables tracking and quantitative imaging of CD8 T cells in cancer patients, enabling confirmation of drug mechanism and indication of the cancer immunotherapies’ efficacy. Previous clinical studies have shown the clinical relevance of ImaginAb’s 89Zr CD8 Immuno-PET imaging agent, and the use of these imaging data sets potentially contributes to improving the standard of care in immune-oncology therapies. The company’s goal is to enable widespread use and adoption of 89Zr CD8 Immuno-PET technology. ImaginAb’s CEO, Ian Wilson, commented: “We are delighted and very excited to work with NEUVOGEN and support the clinical development of their novel therapeutic cancer vaccine candidates. CD8 T cells play a pivotal role in cancer immunotherapy and our clinical studies have shown our 89Zr CD8 Immuno-PET imaging agent tracks and quantifies CD8 T cells in patients. We believe combining CD8 imaging with NEUVOGEN’s whole cell cancer vaccines will enable more robust clinical data sets and accelerate the development of novel treatment protocols for solid tumors.” NEUVOGEN’s next-generation whole cell cancer vaccines are designed to simultaneously prime the broadest array of tumor targets, impacting multiple biologic pathways with the goal of directing an immune response against overlapping targets on every cell within a tumor. ImaginAb’s T Cell specific PET imaging technology allows the NEUVOGEN team to visualize Tumor Infiltrating Lymphocytes, and monitor the dynamics of CD8 T cells in response to its novel cancer vaccine therapies, without the need for multiple tumor biopsies. “This agreement provides NEUVOGEN access to highly specific and precise imaging of the presence of CD8 T Cells in solid tumors over time.” said Todd Binder, Chief Executive Officer, NEUVOGEN. “ImaginAb’s 89Zr CD8 Immuno-PET imaging agent will help our development teams determine changes in CD8 T cell tumor infiltrates induced by NEUVOGEN’s therapies, an important indicator of a patient’s successful immune response to our vaccine therapy.” About ImaginAb ImaginAb Inc. is a market leading biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is advancing a pipeline of minibodies against oncology and immunology targets including the 89Zr CD8 ImmunoPET targeting CD8 T cells. ImaginAb’s products have the potential to improve patient care and lower healthcare costs. The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine ventures Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com. About CD8 Immuno-PET The 89Zr CD8 Immuno-PET agent ([89Zr]-Df-IAB22M2C) is a Zirconium-89 labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8 T cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes. About NEUVOGEN NEUVOGEN, Inc. is an immune-oncology company focused on whole cell cancer vaccine therapies. NEUVOGEN believes its cancer vaccines have the broadest combination of tumor associated antigens and tumor specific antigens ever delivered in a cancer vaccine and as a result can directly target a greater percentage of cancer cells in a solid tumor than any previous cancer vaccine. Based in San Diego, California, NEUVOGEN’s goal is to develop therapeutic cancer vaccines that activate the body’s immune system to eradicate solid tumors and meaningfully extend the lives of patients while limiting side effects. To learn more, visit www.neuvogen.com. For further information please contact: ImaginAb Ian Wilson [email protected] NEUVOGEN Cyrus Arman [email protected] Christine Dusek [email protected] View original content to download multimedia: http://www.prnewswire.com/news-releases/imaginab-and-neuvogen-announce-licensing-agreement-for-cd8-immunopet-technology-301216608.html SOURCE ImaginAb, Inc. Twittercenter_img WhatsApp Pinterest WhatsApp Twitter Local NewsBusiness Pinterestlast_img read more

Read More